Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Files Simultaneous NDAs For Women’s Health Treatments

This article was originally published in The Pink Sheet Daily

Executive Summary

Wyeth's two submissions include desvenlafaxine succinate for treatment of vasomotor symptoms and bazedoxifene for osteoporosis.

You may also be interested in...



Wyeth Says Fracture Data Review Will Delay Viviant Launch

FDA is expected to issue an “approvable” letter April 23 for the osteoporosis therapy requesting three-year fracture data, pushing action date to year-end.

Wyeth Says Fracture Data Review Will Delay Viviant Launch

FDA is expected to issue an “approvable” letter April 23 for the osteoporosis therapy requesting three-year fracture data, pushing action date to year-end.

BioSante To Launch Hot Flash Drug Elestrin in 2007

Following FDA approval, the product is being positioned as the lowest dose of estradiol for moderate-to-severe hot flashes.

Related Content

Topics

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel